In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Schmidt Malan, Suzannah M ^a   Mishra, Avisya J ^a   Mushtaq, Ammara ^a   Brinkman, Cassandra L ^a   Patela, Robin ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antimicrobial resistance; Gram negative bacilli

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; ERTAPENEM; IMIPENEM; IMIPENEM PLUS RELEBACTAM; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; MK-7655; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CITROBACTER KOSERI; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; DRUG EFFECT; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEPHALOSPORINS; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; IMIPENEM; MICROBIAL SENSITIVITY TESTS; TAZOBACTAM;

EID: 85052017885     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00533-18     Document Type: Article

References (33)

1. Vasoo S, Barreto JN, Tosh PK. 2015. Emerging issues in Gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 90:395–403. https://doi.org/10.1016/j.mayocp.2014.12.002.
2. Bornet C, Davin-Regli A, Bosi C, Pages J-M, Bollet C. 2000. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 38:1048–1052.
3. Syue LS, Chen YH, Ko WC, Hsueh PR. 2016. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents 47:250–258. https://doi.org/10.1016/j.ijantimicag.2015.12.021.
4. Pavez M, Vieira C, de Araujo MR, Cerda A, de Almeida LM, Lincopan N, Mamizuka EM. 2016. Molecular mechanisms of membrane impermeability in clinical isolates of Enterobacteriaceae exposed to imipenem selective pressure. Int J Antimicrob Agents 48:78 – 85. https://doi.org/10.1016/j.ijantimicag.2016.04.016.
5. Giancola SE, Mahoney MV, Bias TE, Hirsch EB. 2016. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manage 12:787–797.
6. Liscio JL, Mahoney MV, Hirsch EB. 2015. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents 46:266–271. https://doi.org/10.1016/j.ijantimicag.2015.05.003.
7. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. 2015. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029–5031. https://doi.org/10.1128/AAC.00830-15.
8. Sucher AJ, Chahine EB, Cogan P, Fete M. 2015. Ceftolozane/tazobactam: a new cephalosporin and beta-lactamase inhibitor combination. Ann Pharmacother 49:1046–1056. https://doi.org/10.1177/1060028015593293.
9. Kohner PC, Robberts FJ, Cockerill FR, Patel R. 2009. Cephalosporin MIC distribution of extended-spectrum--lactamase-and pAmpC-producing Escherichia coli and Klebsiella species. J Clin Microbiol 47:2419–2425. https://doi.org/10.1128/JCM.00508-09.
10. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440–458. https://doi.org/10.1128/CMR.00001-07.
11. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. 2015. Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci 22:90–101. https://doi.org/10.1016/j.sjbs.2014.08.002.
12. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De Partha P, Koh TH, Patel R. 2015. In vitro activity of ceftazidime-avibactam, aztreonam-avibactam and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 59:7842–7846. https://doi.org/10.1128/AAC.02019-15.
13. Cejas D, Fernandez Canigia L, Quinteros M, Giovanakis M, Vay C, Lascia-landare S, Mutti D, Pagniez G, Almuzara M, Gutkind G, Radice M. 2012. Plasmid-encoded AmpC (pAmpC) in Enterobacteriaceae: epidemiology of microorganisms and resistance markers. Rev Argent Microbiol 44: 182–186.
14. Bush K, Bradford PA. 2016. Beta-lactams and beta-lactamase inhibitors: an overview. Cold Spring Harbor Perspect Med 6:a025247. https://doi.org/10.1101/cshperspect.a025247.
15. Bush K. 2015. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483–493. https://doi.org/10.1016/j.ijantimicag.2015.08.011.
16. Eckmann C, Solomkin J. 2015. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections. Expert Opin Pharmacother 16:271–280. https://doi.org/10.1517/14656566.2015.994504.
17. Skalweit MJ. 2015. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Des Devel Ther 9:2919–2925. https://doi.org/10.2147/DDDT.S61436.
18. D’Andrea MM, Arena F, Pallecchi L, Rossolini GM. 2013. CTX-M-type -lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 303:305–317. https://doi.org/10.1016/j.ijmm.2013.02.008.
19. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 57:6305–6310. https://doi.org/10.1128/AAC.01802-13.
20. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290.
21. Sacha P, Ostas A, Jaworowska J, Wieczorek P, Ojdana D, Ratajczak J, Tryniszewska E. 2009. The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli. Folia His-tochem Cytobiol 47:537–543.
22. Balm M, La MV, Krishnan P, Jureen R, Lin R, Teo J. 2013. Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. Clin Microbiol Infect 19:E421–E423. https://doi.org/10.1111/1469-0691.12247.
23. NDM) in Gram-negative bacilli. J Clin Microbiol 51:1269–1271. https://doi.org/10 .1128/JCM.03062-12.
24. Koh TH, Cao D, Shan QY, Bacon A, Hsu L-Y, Ooi EE. 2013. Acquired carbapenemases in Enterobactericeae in Singapore, 1996–2012. Pathology 45:600–603. https://doi.org/10.1097/PAT.0b013e3283650b1e.
25. Poirel L, Héritier C, Tolün V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22. https://doi.org/10.1128/AAC.48.1.15-22.2004.
26. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo J-D, Nordmann P. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo--lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 44:891–897. https://doi.org/10.1128/AAC.44.4.891-897.2000.
27. Teo J, Kurup A, Lin R, Hsien K. 2013. Emergence of clinical Klebsiella pneumoniae producing OXA-232 carbapenemase in Singapore. New Microbes New Infect 1:13–15. https://doi.org/10.1002/2052-2975.4.
28. Teo J, Ngan G, Balm M, Jureen R, Krishnan P, Lin R. 2012. Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals. Western Pac Surveill Response J 3:19. https://doi.org/ 10.5365/wpsar.2011.2.4.010.
29. Teo JW, La M-V, Krishnan P, Ang B, Jureen R, Lin RT. 2013. Enterobacter cloacae producing an uncommon class A carbapenemase, IMI-1, from Singapore. J Med Microbiol 62:1086–1088. https://doi.org/10.1099/jmm.0.053363-0.
30. Robberts F, Kohner P, Patel R. 2009. Unreliable extended-spectrum -lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J Clin Microbiol 47:358–361. https://doi.org/10.1128/JCM.01687-08.
31. Cunningham SA, Vasoo S, Patel R. 2016. Evaluation of the Check-Points Check MDR CT103 and CT103 XL microarray kits by use of preparatory rapid cell lysis. J Clin Microbiol 54:1368–1371. https://doi.org/10.1128/JCM.03302-15.
32. Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. CLSI document M07. Clinical and Laboratory Standards Institute, Wayne, PA.
33. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing, 28th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.